Patient and Tumor Characteristics
| Characteristic | All patients* (n = 61) | TRG1 (n = 25) | TRG2–TRG4 (n = 35) | P† |
| Sex | 0.40 | |||
| Male | 37 (61%) | 16 | 20 | |
| Female | 24 (39%) | 9 | 15 | |
| Age (y) | 0.40 | |||
| Median | 59 | 59 | 60 | |
| Range | 43–74 | 47–74 | 43–69 | |
| ECOG performance status | 0.20 | |||
| 0 | 30 (49%) | 10 | 20 | |
| 1 or 2 | 31 (51%) | 15 | 15 | |
| Gunderson risk | 0.21 | |||
| Intermediate (T3N0) | 4 (6%) | 0 | 4 | |
| Moderately high | ||||
| T3N1 | 20 (33%) | 8 | 12 | |
| T4N0 | 2 (3%) | 1 | 0 | |
| High | ||||
| T3N2 | 24 (39%) | 9 | 15 | |
| T4N1–N2 | 3 (5%) | 1 | 2 | |
| AnyTanyNM1 | 8 (13%) | 6 | 2 | |
| Distance from anal verge | 0.34 | |||
| ≤5 cm (low-lying tumor) | 34 (56%) | 15 | 18 | |
| >5 cm (mid/upper tumor) | 27 (44%) | 10 | 17 | |
| Distance from mesorectal fascia | 0.40 | |||
| ≤2 mm | 32 (52%) | 15 | 16 | |
| >2 mm | 25 (41%) | 10 | 15 | |
| Not evaluated‡ | 4 (7%) | 0 | 4 | |
| Baseline CEA serum level | 0.60 | |||
| ≤5 IU/L | 38 (62%) | 16 | 22 | |
| >5 IU/L | 23 (38%) | 9 | 13 |